Itam

Sitagliptin, the active ingredient in Itam, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used in combination with diet and exercise.

GNH USA supplies Itam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. The company adheres to stringent manufacturing standards and provides reliable logistics for timely delivery.

Sitagliptin is used in the treatment of type 2 diabetes, a chronic metabolic disorder characterized by elevated blood glucose. - Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c levels when combined with diet and exercise. - Type 2 diabetes mellitus (as add‑on therapy): provides additional glycemic reduction when combined with other antidiabetic agents such as metformin. - Type 2 diabetes mellitus (monotherapy): can be used alone to achieve target glucose control in patients intolerant to other agents.

Sitagliptin may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Upper respiratory tract infection - Nasopharyngitis - Diarrhea - Arthralgia

Serious or Rare Side Effects: - Acute pancreatitis - Severe allergic reactions (anaphylaxis) - Bullous skin disorders - Hepatic injury - Severe joint pain - Angioedema or hypersensitivity reactions

Before initiating therapy, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required based on renal function. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pancreatitis risk: monitor for persistent abdominal pain. - Cardiovascular disease: no specific contraindication but monitor in patients with heart disease. - Store at room temperature: keep in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce sitagliptin exposure. - Concurrent use of another DPP‑4 inhibitor: duplicate therapy should be avoided. - Co‑administration with potent diuretics in dehydrated patients: may increase risk of renal impairment.

Moderate Interactions (Monitor Closely): - Metformin: monitor renal function to reduce risk of lactic acidosis. - ACE inhibitors or ARBs: observe renal parameters when combined. - Warfarin: periodic INR checks are advisable as sitagliptin may affect anticoagulation control.